Capricor Therapeutics Announces $150 Million Public Offering
Capricor Therapeutics, Inc. (NASDAQ: CAPR), a pioneering biotechnology company, has recently made headlines with its $150 million public offering of common stock. The company specializes in the development of transformative cell and exosome-based therapeutics, particularly focusing on rare diseases.
Details of the Offering
The public offering entails 6,000,000 shares of common stock priced at $25.00 per share. In addition, the company has provided underwriters with a 30-day option to purchase an extra 900,000 shares at the same price. The expected closing of the offering is around December 8, 2025, contingent upon standard closing conditions being met.
Projected Proceeds and Their Uses
With gross proceeds anticipated to reach $150 million before any deductions for underwriting discounts and expenses, Capricor is poised to enhance its capital structure significantly. The proceeds will play a vital role in continuing the development of their current product candidates, supporting manufacturing processes, and financing general corporate activities.
Strategic Management of the Offering
Piper Sandler and Oppenheimer & Co. are leading the offering as joint book-running managers, while H.C. Wainwright & Co. is serving as the co-manager. Such experienced oversight aims to ensure a smooth process for the issuance and distribution of these securities.
Innovation at Capricor
Capricor Therapeutics is at the forefront of medical innovation, particularly with its lead candidate, Deramiocel. As an allogeneic cardiac-derived cell therapy, Deramiocel is currently undergoing late-stage clinical development targeting Duchenne muscular dystrophy (DMD). The therapy has shown remarkable promise in preclinical and clinical studies, demonstrating immunomodulatory and anti-fibrotic effects that could significantly benefit patients suffering from DMD.
Commitment to Advancements in Therapeutics
The company is also harnessing its StealthX™ platform to develop exosome-based therapies aimed at improving vaccination techniques and delivering potent treatments for a variety of conditions. This innovative approach underscores Capricor's dedication to pushing boundaries in healthcare, striving to create impactful therapies.
Collaboration and Future Prospects
Capricor has entered into a partnership with Nippon Shinyaku Co., Ltd. for the exclusive commercialization and distribution of Deramiocel in specific regions, pending regulatory approval. This collaboration is a strategic part of how Capricor plans to expand its market presence and deliver transformative health solutions.
Company Contacts for Further Information
For those interested in more information about Capricor Therapeutics, media inquiries can be directed to Raquel Cona from KCSA Strategic Communications at 212.896.1204 or rcona@kcsa.com. Additionally, AJ Bergmann, the Chief Financial Officer, can be reached at 858.727.1755 or abergmann@capricor.com.
Frequently Asked Questions
What is the main focus of Capricor Therapeutics?
Capricor focuses on developing innovative cell and exosome-based therapeutics to address unmet needs in rare diseases.
How many shares are being offered in the public offering?
The public offering includes 6,000,000 shares of common stock with the potential for an additional 900,000 shares.
What will the proceeds from the offering be used for?
The proceeds will support the development and manufacturing of product candidates, and provide funding for general corporate purposes.
Who are the managers of the public offering?
Piper Sandler and Oppenheimer & Co. are the joint book-running managers of the public offering.
What is Deramiocel?
Deramiocel is Capricor's lead product candidate, designed as an allogeneic cardiac-derived cell therapy for treating Duchenne muscular dystrophy.
